The development of an end-to-end service solution to support lupus patients and improve their experience in clinical trials.


Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 16 11 2018
medline: 18 3 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

To develop an end-to-end clinical trial service to improve patient experience during trials, reduce the burden of participating in a trial, and increase trial retention. A literature search and stakeholder interviews were used to identify current challenges and unmet needs of systemic lupus erythematosus patients and other systemic lupus erythematosus clinical trial stakeholders. The results from the literature search and interviews were used to create a five-phase map describing the current clinical trial experience of all stakeholders. A set of proposed solutions were developed to address the identified unmet needs and challenges. These solutions were presented to trial-experienced patients and study site personnel; any feedback obtained was used to further refine the solutions. Four site personnel and seven patients from three different systemic lupus erythematosus clinical trial sites were interviewed between September 2015 and December 2015. Key unmet needs and challenges were identified at each stage of the clinical trials. At the screening stage, some patients incorrectly thought they were successfully enrolled into the clinical trial. During enrollment, some patients found it difficult to keep fully informed about the trial and were unable to explain the trial process to loved ones. During the trial, patients struggled to prepare for study visits, felt overwhelmed by the trial process, and wanted someone to talk to for support. Clinical trial site personnel reported current key challenges as: delivering trial information clearly and consistently to patients, setting patient expectations, retaining enrolled patients, and providing non-clinical patient support. To address the needs of patients and site personnel, an end-to-end support service was designed, consisting of nine solutions: My Best Choice, My Eligibility, My Lupus Trial Kit, My Lupus Trial Coach, My Appointment Guide, My Clinic Compass, Our Gratitude, Building a Different Network, and My Next Chapter. The solutions proposed in this qualitative study may help improve the systemic lupus erythematosus clinical trial experience for patients, potentially helping to increase trial recruitment and retention. The solutions proposed here would also promote positive patient-trial personnel relationships, which may help site personnel identify patients at risk of early withdrawal, while ensuring that the time and resources of site personnel are used efficiently.

Identifiants

pubmed: 30428691
doi: 10.1177/1740774518811111
pmc: PMC6364094
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-80

Références

Arthritis Rheum. 2007 Feb 15;57(1):49-55
pubmed: 17266094
J Manag Care Spec Pharm. 2017 Aug;23(8):859-867
pubmed: 28737994
J Multidiscip Healthc. 2011 Apr 05;4:63-72
pubmed: 21594059
Patient Prefer Adherence. 2016 Apr 28;10:711-25
pubmed: 27175071
Arthritis Rheumatol. 2014 Feb;66(2):357-68
pubmed: 24504808
N Engl J Med. 2015 Jul 2;373(1):8-9
pubmed: 26132938
Dtsch Arztebl Int. 2015 Jun 19;112(25):423-32
pubmed: 26179016
Rheum Dis Clin North Am. 2014 Aug;40(3):553-9, ix
pubmed: 25034162
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):551-561
pubmed: 28721860
Clin Rheumatol. 2017 Mar;36(3):555-562
pubmed: 27848056
Br J Clin Pharmacol. 1993 Feb;35(2):204-7
pubmed: 8443040
BMJ Open. 2014 Aug 19;4(8):e005734
pubmed: 25138811
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
Arthritis Rheum. 2005 Oct 15;53(5):718-23
pubmed: 16208639
Health Technol Assess. 1999;3(20):1-143
pubmed: 10683591
Acad Med. 2011 Nov;86(11):1360-6
pubmed: 21952064
Br J Cancer. 2014 Jul 8;111(1):1-7
pubmed: 24892447
Trials. 2013 Jun 09;14:166
pubmed: 23758961
Ann Rheum Dis. 2016 Jan;75(1):136-41
pubmed: 25265938
Patient Prefer Adherence. 2017 Jul 31;11:1295-1307
pubmed: 28814837

Auteurs

Jodie Allen (J)

1 UCB Pharma, Slough, UK.

Abbey Child (A)

1 UCB Pharma, Slough, UK.

Sarah Mertens (S)

2 UCB Pharma, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH